In the last decades, the modulation studies of GLYI expression/activity have received growing attention in mammalian systems for the key role of this enzyme in obesity, diabetes, cardiovascular diseases, chronic renal failure, cancer, neurological disorders (Rabbani et al., 2016). Here, GLO1 is linked to chronic kidney disease.